Genetic Engineering Technique in Virus-Like Particle Vaccine Construction

Vaccine becomes a very effective strategy to deal with various infectious diseases even to the point of eradication as in the smalpox virus. At present many conventional vaccines such as inactivated and live-attenuated vaccines. However, these vaccine methods have side effects on the population. Viral-like particle (VLP) is an alternative vaccine based on recombinant DNA technology that is safe with the same immunogenicity as conventional viruses. This vaccine has been shown to induce humoral immune responses mediated by antibodies and cellular immune responses mediated by cytotoxic T cells. With these advantages, currently various types of vaccines have only been developed on a VLP basis. VLP can be produced from a variety of recombinant gene expression systems including bacterial cell expression systems, yeast cells, insect cells, mammalian cells, plant cells, and cell-free systems.

Structural and Functional Characterization of a Novel Recombinant Antimicrobial Peptide from Hermetia illucens

Antibiotics are commonly used to treat pathogenic bacteria, but their prolonged use contributes to the development and spread of drug-resistant microorganisms raising the challenge to find new alternative drugs. Antimicrobial peptides (AMPs) are small/medium molecules ranging 10–100 residues synthesized by all living organisms and playing important roles in the defense systems. These features, together with the inability of microorganisms to develop resistance against the majority of AMPs, suggest that these molecules might represent effective alternatives to classical antibiotics. Because of their high biodiversity, with over one million described species, and their ability to live in hostile environments, insects represent the largest source of these molecules. However, production of insect AMPs in native forms is challenging. In this work we investigate a defensin-like antimicrobial peptide identified in the Hermetia illucens insect through a combination of transcriptomics and bioinformatics approaches. The C-15867 AMP was produced by recombinant DNA technology as a glutathione S-transferase (GST) fusion peptide and purified by affinity chromatography. The free peptide was then obtained by thrombin proteolysis and structurally characterized by mass spectrometry and circular dichroism analyses. The antibacterial activity of the C-15867 peptide was evaluated in vivo by determination of the minimum inhibitory concentration (MIC). Finally, crystal violet assays and SEM analyses suggested disruption of the cell membrane architecture and pore formation with leaking of cytosolic material.

Nursing Skill and Responsibility in Administration of Injection Actilyse

Actilyse can break blood clots that form in the heart, blood arteries, or lungs during a heart attack. This medication is also given to stroke patients to improve recovery and reduce the likelihood of impairment. Recombinant DNA technology was used to create Activase, a tissue plasminogen activator. It is a sterile, purified glycoprotein of 527 amino acids. It is made by combining complementary DNA (cDNA) from a human melanoma cell line with the natural human tissue-type plasminogen activator. After reconstitution with Sterile Water for Injection, USP, Activase is a sterile, white to off-white lyophilized powder for intravenous injection.

Towards the development of a chemical lure to improve the management of invading rat populations

<p>Introduced species, such as Rattus norvegicus and Rattus rattus,have contributed to the extinction of many native animals and plants in New Zealand(NZ). Current strategies exist to monitor, manage and eradicate pest species. However, these haven’t always been completely successful and tools to detect small or invading densities remain to be developed. One possible new method to address this problem is the application of chemical attractants (lures). Recently, a major urinary protein (MUP) has been shown in male miceto act as a sexual attractant. MUPs modulate the release of volatile attractants and have potential to act as attractants themselves. Our aim was to determine if a similar MUP(s) and associated volatiles are present in the urine of rats, with the prospect of creating a chemical lure to use in rat detection and eradication. Using Gas Chromatography/Mass Spectrometry, potential volatiles in rat urine have been identified. Analysis of rat urine by gel electrophoresis has shown MUPs present in both sexes. A 22.4 kDa MUP in Rattus norvegicushas been synthesised and expressed in E.coliusing recombinant DNA technology. Preliminary steps have been made towards the production of a MUP based on ship rat DNA sequence. Future behavioral trials are needed to investigate whether the synthesised protein, in the presence or absence of the urinary-derived volatiles, is a sexual attractant.</p>

Towards the development of a chemical lure to improve the management of invading rat populations

<p>Introduced species, such as Rattus norvegicus and Rattus rattus,have contributed to the extinction of many native animals and plants in New Zealand(NZ). Current strategies exist to monitor, manage and eradicate pest species. However, these haven’t always been completely successful and tools to detect small or invading densities remain to be developed. One possible new method to address this problem is the application of chemical attractants (lures). Recently, a major urinary protein (MUP) has been shown in male miceto act as a sexual attractant. MUPs modulate the release of volatile attractants and have potential to act as attractants themselves. Our aim was to determine if a similar MUP(s) and associated volatiles are present in the urine of rats, with the prospect of creating a chemical lure to use in rat detection and eradication. Using Gas Chromatography/Mass Spectrometry, potential volatiles in rat urine have been identified. Analysis of rat urine by gel electrophoresis has shown MUPs present in both sexes. A 22.4 kDa MUP in Rattus norvegicushas been synthesised and expressed in E.coliusing recombinant DNA technology. Preliminary steps have been made towards the production of a MUP based on ship rat DNA sequence. Future behavioral trials are needed to investigate whether the synthesised protein, in the presence or absence of the urinary-derived volatiles, is a sexual attractant.</p>

If Not Now, When? Nonserotype Pneumococcal Protein Vaccines

The sudden emergence and global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have greatly accelerated the adoption of novel vaccine strategies, which otherwise would have likely languished for years. In this light, vaccines for certain other pathogens could certainly benefit from reconsideration. One such pathogen is Streptococcus pneumoniae (pneumococcus), an encapsulated bacterium that can express &gt;100 antigenically distinct serotypes. Current pneumococcal vaccines are based exclusively on capsular polysaccharide—either purified alone or conjugated to protein. Since the introduction of conjugate vaccines, the valence of pneumococcal vaccines has steadily increased, as has the associated complexity and cost of production. There are many pneumococcal proteins invariantly expressed across all serotypes, which have been shown to induce robust immune responses in animal models. These proteins could be readily produced using recombinant DNA technology or by mRNA technology currently used in SARS-CoV-2 vaccines. A door may be opening to new opportunities in affordable and broadly protective vaccines.

A comprehensive comparison between camelid nanobodies and single chain variable fragments

By the emergence of recombinant DNA technology, many antibody fragments have been developed devoid of undesired properties of natural immunoglobulins. Among them, camelid heavy-chain variable domains (VHHs) and single-chain variable fragments (scFvs) are the most favored ones. While scFv is used widely in various applications, camelid antibodies (VHHs) can serve as an alternative because of their superior chemical and physical properties such as higher solubility, stability, smaller size, and lower production cost. Here, these two counterparts are compared in structure and properties to identify which one is more suitable for each of their various therapeutic, diagnosis, and research applications.

RISPR-Cas9: a weapon against COVID-19

In current pandemic circumstances, novel coronavirus is a salutary challenge for all over the world and coronavirus used the host cell for replication. Coronavirus usually use the host cellular products to perform their basic functions. Various specific target sites also present in coronavirus proteins for target-specific therapy such as small inhibitor molecule for viral polymerase or prevent the attachment of viruses to the receptor sites for vaccination purpose. The virus attaches to ACE2 receptors and uses enzyme to cleave translated products which encodes for various enzymes like RNA polymerase, helicase etc. The system needs some processes which lead for the disturbance and make the virus unable to replicate. The recombinant DNA technology makes a great advancement in every field of life with a number of importance in agriculture, industries, and clinics. It is used to manipulate the genetic material of living organism for the purpose of producing desirable products such as disease resistant crops, treatment of cancer, genetic disease and viral disease. Thus, for the purpose of antiviral strategies, the specific technique called CRISPR/Cas9 is used, and this technique has the capability to target specific nucleotide sequence inside the genome of coronavirus.